{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-151049","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.712238+00:00","generated_at":"2026-06-01T07:08:19.422009+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Karyopharm shareholders approve 6M share increase in equity plan, 5M in ESPP, and option exchange","bullets":["Stockholders approved Class II directors: Deepika R. Pakianathan, Richard Paulson, Chen Schor (all three-year terms).","Amendment to 2022 Equity Plan approved: adds 6,000,000 shares for issuance.","ESPP Amendment approved: adds 5,000,000 shares for issuance.","Stockholders approved a one-time stock option exchange program for non-executive officer employees.","Ratified Ernst & Young as independent auditor for FY2024 (87.7M for, 2.5M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-151049","json":"https://secwatch.observer/filing/0001193125-24-151049.json","markdown":"https://secwatch.observer/filing/0001193125-24-151049.md","text":"https://secwatch.observer/filing/0001193125-24-151049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524151049/0001193125-24-151049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312524151049/d827879d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:08:19.422009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}